Halozyme Therapeutics Says Was Informed by License Partner Roche That There Will Be A Delay In Projected Launch Timing For Tecentriq SC With ENHANZE In The US
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics has been informed by its license partner Roche that there will be a delay in the projected launch timing for Tecentriq SC with ENHANZE in the US.
September 07, 2023 | 11:19 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Halozyme Therapeutics' stock may be negatively impacted due to the delay in the launch of Tecentriq SC with ENHANZE in the US.
Halozyme Therapeutics is directly involved in the development of Tecentriq SC with ENHANZE. The delay in its launch in the US market could potentially impact the company's projected revenues and thus negatively affect its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100